Skip to main content

Corporate News tagged:

Drug discovery

REPROCELL Corporate News

[PRESS RELEASE:] REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)

08 February 2024

REPROCELL currently has two clinical pipelines under research and development: (1.) the stem cell product Stemchymal for spinocerebellar ataxia; (2.) iPSC-derived neuroglial cells for ALS (Amyotrophic Lateral Sclerosis). REPROCELL will soon...

End of 2023 Newsletter

15 December 2023

The end of the year might be approaching, but we’re not winding down at REPROCELL. The final half of 2023 has brought new services, collaborations, partnerships, and successes to enrich your stem cell and drug discovery research. This inclu...

REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study

24 October 2023

On 16 October 2023, Silo Pharma announced positive data for the effects of SPU-21 in inflamed human synovial tissue to inhibit the progression of rheumatoid arthritis (RA). Preclinical data from fresh human tissue “The purpose of this study...

Simplifying AI data analysis for scientists – as REPROCELL, IBM and STFC Hartree Centre successfully launch Pharmacology-AI platform

01 June 2023

01 June 2023, Glasgow, UK and Daresbury, UK: REPROCELL today announces the launch of a new commercial service, Pharmacology-AI. The launch follows the completion of one of the first EXCELERATE projects, by the Hartree National Centre for Di...

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

09 December 2022

Silo Pharma, Inc. has announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons. Conducted in partners...

Building economic resilience and unleashing productivity through digital innovation

09 November 2022

UK enterprises are facing a number of disruptive forces that necessitate transformation at pace – macro-economic challenges, socio-political challenges, and the focus on our own resilience. Industries from across the country are in the grip...

REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine

31 August 2022

New collaboration at Hartree National Centre for Digital Innovation combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in artificial intelligence and machine learning. Glasgow, UK and Daresbury, UK: REPRO...

Preclinical studies by REPROCELL give COPD drug a final boost before clinical trials

17 August 2022

Glasgow UK - 17 August 2022: A drug being developed for the treatment of severe asthma and COPD has passed an important milestone. Scientists at REPROCELL compared the effects of the compound, RCD405, with drugs that are currently used to t...

Life science after lockdown: SPS returns for 2022

15 August 2022

Next month, the Safety Pharmacology Society (SPS) will be hosting its first in-person meeting since 2019. Now in its 22nd year, this dynamic forum is known for its global networking opportunities and events promoting the best practices in s...

REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development

08 March 2022

Glasgow UK - 25 February 2022: REPROCELL, in collaboration with researchers at IBM and the Precision Medicine Scotland Innovation Centre, have co-authored a publication aiming to improve precision medicine strategies. The paper, titled "Com...

REPROCELL spotlights the power of smarter biospecimens in new global publication

21 January 2022

Glasgow UK - 21 January 2022: REPROCELL has published an article highlighting the power of human biospecimens in the latest issue of European Biopharmaceutical Review (EBR). The piece, titled Dynamizing Biomarker R&D with Smarter Biospecime...

Hoth Therapeutics Extends Partnership Agreement with REPROCELL

25 October 2021

GLASGOW, October 25, 2021: Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh explants of ulcerativ...

REPROCELL highlights the power of human fresh tissue in global publication

05 July 2021

Glasgow, UK: REPROCELL employees, Zara Puckrin and Graeme Macluskie, have published a headline article in the latest issue of European Biopharmaceutical Review (EBR). The piece, titled "Human Fresh Tissue VS Clinical Attrition", explains th...

Hoth Therapeutics Executes Partnership Agreement with REPROCELL to Assess the Effect of HT-003 Therapeutic Platform on Inflammatory Bowel Disease

15 March 2021

NEW YORK, March 11, 2021/PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a partnership agreement with REPROCELL, a contract research organization (CRO), providing a unique co...

eTheRNA-led international consortium starts preclinical studies of cross-strain protective COVID-19 mRNA vaccine for high risk populations

16 July 2020

March 19, 2020 Niel, Belgium, (‘eTheRNA’ or The Company’), a clinical-stage company developing vaccines from its proprietary mRNA TriMix platform, today announced that the consortium it leads with Chinese, North American and European partne...

Why eTheRNA's mRNA vaccine may offer a long-term solution to COVID

13 July 2020

REPROCELL has recently joined an international consortium, led by Belgium company etheRNA, to develop a novel mRNA vaccine against CoV-2. Administered intranasally, the proposed vaccine is intended primarily for high risk populations such a...

Patients with IBD absorb drugs differently from healthy individuals

16 January 2020

A recent study by researchers from REPROCELL found that IBD patients display different drug absorption profiles to healthy individuals. This is the first time that drug absorption has been estimated using inflamed GI tissue from this patien...

REPROCELL can now predict oral bioavailability in fresh IBD tissue

14 January 2020

Glasgow, UK: REPROCELL (Biopta) today announced that they can predict test article permeability using gastrointestinal (GI) resections from Inflammatory Bowel Disease (IBD) donors. This service, which is first of its kind to market, will al...

Early understanding of pharmacology and genomics can improve precision medicine strategies

23 December 2019

Glasgow, UK: REPROCELL (Biopta) today announced the successful publication of a novel study in pharmacology and genomics to improve strategies for the development of precision medicines. The study – performed in collaboration with the NHS, ...

Lantern Pharma Selects REPROCELL Inc., for Drug Screening and Biomarker Discovery Services

13 November 2019

Lantern Pharma a clinical stage oncology biotech leveraging A.I. and machine learning genomics company has selected REPROCELL Inc. to provide drug screening and drug sensitivity services. BELTSVILLE, MD. (PRWEB) NOVEMBER 12, 2019: REPROCELL...